10 years ahead in neurodegenerative disease with BrainDTech

24 February 2020
  • Portfolio
  • /

    The startup BrainDTech can identify biomarkers for neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s) years before symptoms appear.

    Founded in 2016, BrainDTech is an innovative startup within the Bio4Dreams network that has developed a cutting-edge approach to identifying biomarkers for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, years before the appearance of any symptoms.

    Anticipating the onset of symptoms

    Currently, the diagnosis of neurological and neurodegenerative diseases (such as Alzheimer’s and Parkinson’s) is made by observing clinical symptoms.

    However, these symptoms manifest when the diseases are already well-established, and the available treatments only aim to contain the symptoms and progression of the disease.

    Early diagnosis

    It is now scientifically established that to adequately address neurological and neurodegenerative diseases, it is crucial to act before their onset and initiate diagnostic and therapeutic pathways promptly, even before the clinical symptoms manifest.

    In this context, BrainDTech has developed an innovative approach that detects the presence of biomarkers in microvesicles released by cells of the nervous system (particularly by microglia) following neuroinflammation. Their specificity allows for distinguishing between different neurodegenerative diseases.

    This approach is also useful for classifying patients according to the stages of the disease, as well as for monitoring the effectiveness of a treatment.

    The earlier, the better.

    Fabio Bianco, CEO BrainDTech

    Updates

    September 2021

    πŸ“ˆ BrainDTech officially becomes an innovative SME.

    πŸ“—Β Learn more about BrainDTech and about other entities in our portfolio.

    10 years ahead in neurodegenerative disease with BrainDTech

    24 February 2020
  • Portfolio
  • /

    The startup BrainDTech can identify biomarkers for neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s) years before symptoms appear.

    Founded in 2016, BrainDTech is an innovative startup within the Bio4Dreams network that has developed a cutting-edge approach to identifying biomarkers for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, years before the appearance of any symptoms.

    Anticipating the onset of symptoms

    Currently, the diagnosis of neurological and neurodegenerative diseases (such as Alzheimer’s and Parkinson’s) is made by observing clinical symptoms.

    However, these symptoms manifest when the diseases are already well-established, and the available treatments only aim to contain the symptoms and progression of the disease.

    Early diagnosis

    It is now scientifically established that to adequately address neurological and neurodegenerative diseases, it is crucial to act before their onset and initiate diagnostic and therapeutic pathways promptly, even before the clinical symptoms manifest.

    In this context, BrainDTech has developed an innovative approach that detects the presence of biomarkers in microvesicles released by cells of the nervous system (particularly by microglia) following neuroinflammation. Their specificity allows for distinguishing between different neurodegenerative diseases.

    This approach is also useful for classifying patients according to the stages of the disease, as well as for monitoring the effectiveness of a treatment.

    The earlier, the better.

    Fabio Bianco, CEO BrainDTech

    Updates

    September 2021

    πŸ“ˆ BrainDTech officially becomes an innovative SME.

    πŸ“—Β Learn more about BrainDTech and about other entities in our portfolio.

    10 years ahead in neurodegenerative disease with BrainDTech

    24 February 2020
  • Portfolio
  • /

    The startup BrainDTech can identify biomarkers for neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s) years before symptoms appear.

    Founded in 2016, BrainDTech is an innovative startup within the Bio4Dreams network that has developed a cutting-edge approach to identifying biomarkers for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, years before the appearance of any symptoms.

    Anticipating the onset of symptoms

    Currently, the diagnosis of neurological and neurodegenerative diseases (such as Alzheimer’s and Parkinson’s) is made by observing clinical symptoms.

    However, these symptoms manifest when the diseases are already well-established, and the available treatments only aim to contain the symptoms and progression of the disease.

    Early diagnosis

    It is now scientifically established that to adequately address neurological and neurodegenerative diseases, it is crucial to act before their onset and initiate diagnostic and therapeutic pathways promptly, even before the clinical symptoms manifest.

    In this context, BrainDTech has developed an innovative approach that detects the presence of biomarkers in microvesicles released by cells of the nervous system (particularly by microglia) following neuroinflammation. Their specificity allows for distinguishing between different neurodegenerative diseases.

    This approach is also useful for classifying patients according to the stages of the disease, as well as for monitoring the effectiveness of a treatment.

    The earlier, the better.

    Fabio Bianco, CEO BrainDTech

    Updates

    September 2021

    πŸ“ˆ BrainDTech officially becomes an innovative SME.

    πŸ“—Β Learn more about BrainDTech and about other entities in our portfolio.

    10 years ahead in neurodegenerative disease with BrainDTech

    24 February 2020
  • Portfolio
  • /

    The startup BrainDTech can identify biomarkers for neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s) years before symptoms appear.

    Founded in 2016, BrainDTech is an innovative startup within the Bio4Dreams network that has developed a cutting-edge approach to identifying biomarkers for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, years before the appearance of any symptoms.

    Anticipating the onset of symptoms

    Currently, the diagnosis of neurological and neurodegenerative diseases (such as Alzheimer’s and Parkinson’s) is made by observing clinical symptoms.

    However, these symptoms manifest when the diseases are already well-established, and the available treatments only aim to contain the symptoms and progression of the disease.

    Early diagnosis

    It is now scientifically established that to adequately address neurological and neurodegenerative diseases, it is crucial to act before their onset and initiate diagnostic and therapeutic pathways promptly, even before the clinical symptoms manifest.

    In this context, BrainDTech has developed an innovative approach that detects the presence of biomarkers in microvesicles released by cells of the nervous system (particularly by microglia) following neuroinflammation. Their specificity allows for distinguishing between different neurodegenerative diseases.

    This approach is also useful for classifying patients according to the stages of the disease, as well as for monitoring the effectiveness of a treatment.

    The earlier, the better.

    Fabio Bianco, CEO BrainDTech

    Updates

    September 2021

    πŸ“ˆ BrainDTech officially becomes an innovative SME.

    πŸ“—Β Learn more about BrainDTech and about other entities in our portfolio.